Enanta PharmaceuticalsENTA
About: Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Employees: 131
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
10% more call options, than puts
Call options by funds: $54K | Put options by funds: $49K
10% more funds holding
Funds holding: 100 [Q2] → 110 (+10) [Q3]
11.38% less ownership
Funds ownership: 111.37% [Q2] → 100.0% (-11.38%) [Q3]
28% less capital invested
Capital invested by funds: $306M [Q2] → $220M (-$86.4M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 218%upside $20 | Outperform Maintained | 26 Nov 2024 |
JMP Securities Roy Buchanan 19% 1-year accuracy 3 / 16 met price target | 234%upside $21 | Market Outperform Reiterated | 26 Nov 2024 |
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target | 330%upside $27 | Buy Reiterated | 10 Oct 2024 |
Financial journalist opinion
Based on 4 articles about ENTA published over the past 30 days
